Gurkan et al
Ippei Ikushimas institution has also received funding to conduct clinical trials from Novo Nordisk, Eli Lilly and Company, Teijin Pharma, Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Sanofi K.K., Nippon Boehringer Ingelheim Co., and AstraZeneca
Cell Host Microbe 31 , 781797.e789 (2023)
Before initiating Wegovy, healthcare professionals should establish a comprehensive baseline assessment including: Complete medical history and medication review Physical examination with baseline weight, BMI, and blood pressure Blood tests: HbA1c (if diabetic or at risk), lipid profile, liver function, kidney function, and thyroid function Assessment for contraindications (the UK SmPC lists hypersensitivity to semaglutide or any excipients as the only contraindication) Documentation of any existing neurological symptoms According to NICE TA875, Wegovy should be prescribed within specialist weight management services